In vitro experiments revealed that co-treatment with serum containing the Xianhecao-Huanglian drug pair and the JAK2/STAT3 pathway inhibitor AG490 substantially curtailed released inflammatory cytokines and increased their expression in a model of IBD cells. Here, JAK2 is linked to inflammatory bowel disease.